Aspira Women's Health Inc (AWH) - Long-Term Debt to Capital Ratio

Corporate emblem and logo of Aspira Women's Health (AWH)

The historical price chart for Aspira Women's Health (AWH) demonstrates the dynamics of a company whose growth is fueled by sales of OvaSuite systems for early oncology detection, with the indicator standing at 0.00. The business generates revenue from biomarker analysis in gynecology, aiding in the diagnosis of ovarian cancer. Thanks to cloud data processing and AI testing, scaling services requires no capital expenditures, which significantly optimizes the cost of each procedure.

Aspira Women's Health Inc (AWH): Long-Term Debt to Equity from 07/04/2022 to 04/26/2025

Analytical breakdowns for Aspira Women's Health

- market price and analyst price targets:
Market Price Aspira Women's Health, Inc.|AWH - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization Aspira Women's Health Inc.|AWH - Enterprise Value
- issuer book value statistics:
Book Value per Share Aspira Women's Health|AWH - Company Book Value|Capitalization to Book Value Ratio aspirawh.com|AWH - Company Total Assets
- debt and solvency information:
Total Debt to Capital Aspira Women's Health|AWH - Long-Term Debt to Equity|Short-Term Debt to Equity aspirawh.com|AWH - Company Total Debt|Debts to Book Value Aspira Women's Health Inc.|AWH - Company Long-Term Debt|Short-Term Debt Volume Aspira Women's Health|Interim Coverage Ratio aspirawh.com
- net income and valuation ratios data:
AWH - Company Net Income
General company analysis:AWH (Aspira Women's Health, Inc.)
Core merchandise of aspirawh.com

Aspira Women's Health requires balanced financing to scale its biochemical testing network. The ratio compares liabilities with a maturity of more than one year to the amount of equity. By analyzing the proportion of long-term debt to equity, an investor assesses the degree of financial leverage. Excessive debt creates the risk of overpaying on interest. An optimal balance ensures sustainable development without losing control over assets.

Analysis of competing companies

Long-Term Liabilities to Capital Agilent Technologies, Inc. A|Long-Term Debt to Capital DGX|Illumina Platform - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital EXAS (Exact Sciences)|Long-Term Debt to Capital revvity.com RVTY|BIO - Long-Term Debt to Equity|NNNN (Anbio Biotechnology Ltd) - Long-Term Debt to Capital Ratio|SHC: Long-Term Debt to Capital|QuidelOrtho Inc. (QDEL) - Long-Term Debt to Capital|Long-Term Debt to Equity OPKO Health, Inc.|Long-Term Debt to Equity CDNA|Long-Term Debt to Equity Ratio MRVI (Maravai LifeSciences Holdings, Inc.)|FLGT - Long-Term Liabilities to Capital|Long-Term Debt to Equity Fluidigm LAB|Ratio of Long-Term Indebtedness to Capital Cytek Corp (CTKB)|OraSure Technologies - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Exagen Inc. XGN|MDxHealth (MDXH) - Long-Term Debt to Equity|LUCD - Ratio of Long-Term Indebtedness to Capital|PRE (Prenetics Global Limited) - Long-Term Debt to Capital|Long-Term Debt to Capital Insight Molecular|Long-Term Debt to Equity Trinity Biotech plc (TRIB)|Ratio of Long-Term Indebtedness to Capital prophaselabs.com|Long-Term Debt to Equity Ainos AIMD|CODX (Co-Diagnostics Inc) - Long-Term Liabilities to Equity|Heart Test Laboratories Inc. - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Biomerica Inc BMRA|cardiodiagnosticsinc.com (CDIO) - Long-Term Debt to Equity|viraxbiolabs.com - Long-Term Debt to Capital Coefficient|BJDX (Bluejay Diagnostics, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Capital Accelerate Diagnostics Inc.|Long-Term Debt to Equity Ratio CNTG (CENTOGENE, N.V.)|ENZ (enzo.com) - Long-Term Debt to Capital Coefficient|Fresh2 Group - Long-Term Debt to Equity Ratio|GENE - Long-Term Debt to Equity Ratio|ME - Long-Term Debt to Equity|Long-Term Liabilities to Capital Psychemedics Corp.